According to a study from Barcelona, Spain, "The aim of this study was to develop and validate a population pharmacokinetic model for nevirapine in a population of HIV-infected adults and to evaluate the influence of nevirapine dosing regimen and patient characteristics on nevirapine trough concentration. HIV-infected adults receiving oral nevirapine for at least 4 weeks were included."
"A concentration-time profile was obtained for each patient, and nevirapine concentrations in plasma were determined by HPLC. Pharmacokinetic parameters, inter-individual variability and residual error were estimated using non-linear mixed effects modelling. The influence of patient …
Комментариев нет:
Отправить комментарий